Niagen Bioscience, Inc. (NAGE) stock
NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3011% below fair value
$2.04+0.03 (+1.49%)
Close on Nov 17, 2026Market cap $161.42MP/E 17.0Yield –
Niagen Bioscience total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Niagen Bioscience's total debt was $137.00K at Dec 31, 2018. For fiscal 2018 it was $137.00K, down 55.8% from the year before. The highest annual figure on record is $4.87M in fiscal 2015.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $137.00K | -55.8% |
| FY2017 | Dec 30, 2017 | $310.00K | – |
| FY2016 | Dec 31, 2016 | $0 | -100.0% |
| FY2015 | Jan 2, 2016 | $4.87M | +121.5% |
| FY2014 | Jan 3, 2015 | $2.20M | +684.9% |
| FY2013 | Dec 28, 2013 | $280.34K | +88.9% |
| FY2012 | Dec 29, 2012 | $148.37K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2018 | Dec 31, 2018 | $137.00K | – |
| Q4 FY2017 | Dec 30, 2017 | $310.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $0 | – |
| Q3 FY2016 | Oct 1, 2016 | $0 | – |
See a number that looks wrong?